Celldex Therapeutics, Inc.
corporate_fare Company Profile
Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for CLDX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for CLDX spans 8-K, 10-Q, DEF 14A, 424B5.
Recent high-impact activity:
- Celldex Scraps Atopic Dermatitis Program After Phase 2 Itch Data Miss
- Barzolvolimab Fails Phase 2 Atopic Dermatitis Trial; Celldex Drops the Indication
- Celldex Plunges 20% Premarket Despite Positive Phase 3 Hives Data
- Barzolvolimab Clears Every Hurdle in Two Phase 3 CSU Trials
- Celldex's Barzolvolimab Hits All Endpoints in Two Phase 3 CSU Trials
Financial Snapshot
Short Interest & Short Volume
10.35 days to coverFINRA reported short interest of 9,936,646 shares in CLDX as of the October 30, 2026 settlement, a 3.5% increase from the prior period — about 10.3 days to cover at its recent average daily volume. On November 20, 2026, 78.9% of CLDX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for CLDX, detected from its recent SEC filings.
New Universal Shelf Filed · Replaces Expired $300M ATM
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →